Related Experiment Video
Updated: May 22, 2026
10:47
Isolation and Cellular Phenotyping of Mesenchymal Stem Cells Derived from Synovial Fluid and Bone Marrow of Minipigs
Published on: July 2, 2016
Pigmented villonodular synovitis therapy with MSCF-1 inhibitors
1Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. htemple@med.miami.edu
Current Opinion in Oncology
|May 11, 2012
Summary
Imatinib shows promise for treating giant cell tumors and pigmented villonodular synovitis. This targeted therapy may stabilize aggressive or recurrent synovial-based tumors, offering a new treatment avenue.
Area of Science:
- Oncology
- Orthopedics
- Pharmacology
Background:
- Giant cell tumor of tendon sheath (GCT-TS) and pigmented villonodular synovitis (PVNS) are neoplastic conditions originating from the synovium.
- Current standard treatment involves surgical excision, but recurrence and aggressive disease necessitate alternative therapeutic strategies.
Purpose of the Study:
- To review the potential of targeted therapy for GCT-TS and PVNS.
- To explore imatinib as a treatment option for aggressive and recurrent cases.
Main Methods:
- Literature review focusing on targeted therapies for GCT-TS and PVNS.
- Analysis of existing clinical data on imatinib efficacy and safety.
Main Results:
- Imatinib, a tyrosine kinase inhibitor, targets colony-stimulating factor 1 (CSF1) production by tumor cells.
- Clinical data suggest imatinib can stabilize disease in most patients with manageable side effects.
- A subpopulation of tumor cells recruits nonneoplastic cells expressing CSF1.
Conclusions:
- Imatinib represents a promising targeted therapy for GCT-TS and PVNS.
- Other CSF1R inhibitors and monoclonal antibodies may also play a significant role in managing these tumors.
Related Concept Videos
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...